Monascus yellow pigment composition and application thereof, composition with alpha-glucosidase inhibitory activity and application thereof

Abstract

This invention application provides compositions containing red yeast rice pigment and their applications, compositions with α-glucosidase inhibitory activity and their applications, and further, their application in α-glucosidase inhibitors, belonging to the technical field of natural active compounds inhibiting α-glucosidase. The compositions of this invention comprise one or both of red yeast rice pigment and red yeast rice pigment: wherein the molar ratio of acarbose to red yeast rice pigment is 400:400-600:300; the molar ratio of acarbose to red yeast rice pigment is 400:200-600:150; and the molar ratio of red yeast rice pigment to red yeast rice pigment is 150:400-200:300. The compositions involved in this invention have a significant synergistic inhibitory effect on α-glucosidase, superior to using the above compounds alone, and can achieve reduced drug dosage and reduced drug side effects.

Description

Technical Field

[0001] This invention belongs to the field of α-glucosidase inhibitor technology, specifically relating to red yeast rice yellow pigment compositions and their applications, and compositions having α-glucosidase inhibitory activity and their applications. Background Technology

[0002] Diabetes mellitus (DM) has been recognized as a major global public health concern and is gradually becoming one of the most prevalent and challenging health problems worldwide. DM is a chronic metabolic disease caused by insufficient insulin secretion or insulin resistance due to environmental and genetic factors. Its main manifestation is long-term, uncontrollable hyperglycemia, accompanied by a series of complications such as kidney failure, cardiovascular disease, and vision loss. Clinical symptoms include polydipsia, polyuria, weight loss, and fatigue.

[0003] α-glucosidase (EC.3.1.20) is an important carbohydrate hydrolase in human tissues. It is located on the surface of the brush border epithelial cells of the small intestine and directly participates in the digestion of carbohydrates. It plays an important role in regulating glucose utilization and postprandial blood glucose.

[0004] Starchy foods are hydrolyzed into oligosaccharides by saliva and pancreatic α-amylase, and then further hydrolyzed into glucose by α-glucosidase in the small intestine. Finally, glucose is absorbed by the intestinal mucosal cells, thus affecting postprandial blood glucose levels. Studies have shown that α-glucosidase activity is directly related to postprandial blood glucose concentration. High postprandial blood glucose concentration is a major manifestation of type 2 diabetes, and oral α-glucosidase inhibitors are one of the important clinical treatments for type 2 diabetes. Therefore, finding drugs that can effectively inhibit α-glucosidase activity is of great significance for controlling postprandial blood glucose, regulating blood glucose concentration, and preventing diabetic complications.

[0005] Red yeast rice pigment is a natural food coloring agent widely used in the food industry. Due to its unique functional group structure, it plays an important role in antibacterial, anti-inflammatory, lipid-lowering, anti-cancer, anti-obesity, and anti-Alzheimer's disease effects, and is currently widely used in meat products, condiments, brewing, and pharmaceuticals. Among them, ankaflavin and monascin are considered important bioactive components in red yeast rice products, which can exhibit various beneficial effects on human metabolic syndrome, such as anti-inflammation, anti-diabetic effects, and regulation of lipid metabolism, and their safety is higher than that of monacolin K. Therefore, research on the application of red yeast rice pigment in the food and health product industries is of great significance.

[0006] Drug combination therapy refers to the simultaneous or sequential use of two or more drugs to achieve a therapeutic goal. In clinical studies of type 2 diabetes, the use of relatively high doses of a single drug often produces adverse reactions. Compared with increasing the dose of a single drug, combining two drugs can enhance their medicinal value and improve their inhibitory effect. Currently, research on α-glucosidase inhibitors mainly focuses on single compounds, with few reports on synergistic effects between compounds. Therefore, research on red yeast rice yellow pigment or its combination with other glucosidase inhibitors to inhibit α-glucosidase activity and improve hypoglycemic effects is of great significance. Summary of the Invention

[0007] This invention provides a red yeast rice yellow pigment composition with α-glucosidase inhibitory activity. Furthermore, different red yeast rice yellow pigments can be used in combination, or red yeast rice yellow pigments can be used in combination with acarbose, to solve the problems of single active ingredients, limited blood sugar lowering effect, and easy side effects in the prior art.

[0008] To achieve the above objectives, the technical solution adopted by the present invention is as follows:

[0009] This invention first provides the concentration range and IC50 values ​​for the inhibitory effects of monaxitin, monaxitoflavone, and acarbose on α-glucosidase. 50 value.

[0010] A red yeast rice yellow pigment composition comprising one or both of red yeast rice pigment and red yeast rice yellow pigment.

[0011] The molar ratio of acarbose to monaxanthin is 400:400-600:300; the molar ratio of acarbose to monaxanthin is 400:200-600:150; and the molar ratio of monaxanthin to monaxanthin is 150:400-200:300.

[0012] In specific embodiments, when the molar ratio of acarbose to monaxanthin is 400:300 and 400:400, the molar ratio of acarbose to monaxanthin is 400:150 and 400:200, and the molar ratio of monaxanthin to monaxanthin is 150:300 and 200:300, CI < 1, indicating a synergistic effect.

[0013] The use of the above composition in the preparation of inhibitors with α-glucosidase inhibitory ability.

[0014] An α-glucosidase inhibitor, the active ingredient of which comprises one or both of monaxanthin and monaxanthin; wherein the molar ratio of acarbose to monaxanthin is 400:300 and 400:400; the molar ratio of acarbose to monaxanthin is 400:150 and 400:200; and the molar ratio of monaxanthin to monaxanthin is 150:300 and 200:300.

[0015] Advantages of the technical solution of this invention

[0016] At defined molar concentrations, the acarbose, monaxanthin, and monaxanthin compositions exhibit synergistic effects. In vitro α-glucosidase inhibition experiments demonstrated that the monaxanthin and monaxanthin compositions (150:300, 200:300), acarbose and monaxanthin compositions (400:300, 400:400), and acarbose and monaxanthin compositions (400:150, 400:200) of this invention have significant synergistic effects on α-glucosidase inhibition. Attached Figure Description

[0017] Figure 1 Inhibitory activities of monaxiocin, monaxioxin and acarbose on α-glucosidase and IC50 50 value;

[0018] Figure 2 The inhibitory activity of the acarbose and monaxitol (400:300) combination against α-glucosidase;

[0019] Figure 3 Fa-CI curve of acarbose and monaxanthin (400:300) combination against α-glucosidase;

[0020] Figure 4 The inhibitory activity of the acarbose and monaxitol (400:400) combination against α-glucosidase;

[0021] Figure 5 Fa-CI curve of acarbose and monaxanthin (400:400) combination against α-glucosidase;

[0022] Figure 6 The inhibitory activity of the acarbose and monaxitol (600:300) combination against α-glucosidase;

[0023] Figure 7 Fa-CI curve of acarbose and monaxanthin (600:300) combination against α-glucosidase;

[0024] Figure 8 The inhibitory activity of the combination of acarbose and red yeast rice (400:150) on α-glucosidase;

[0025] Figure 9 Fa-CI curve of acarbose and red yeast rice (400:150) combination against α-glucosidase;

[0026] Figure 10 The inhibitory activity of the combination of acarbose and red yeast rice (400:200) on α-glucosidase;

[0027] Figure 11 Fa-CI curve of acarbose and red yeast rice (400:200) combination against α-glucosidase;

[0028] Figure 12 The inhibitory activity of the combination of acarbose and red yeast rice (600:150) on α-glucosidase;

[0029] Figure 13 Fa-CI curve of acarbose and red yeast rice (600:150) combination against α-glucosidase;

[0030] Figure 14 The inhibitory activity of the combination of red yeast rice xanthophyll and red yeast rice (150:300) on α-glucosidase;

[0031] Figure 15 Fa-CI curve of α-glucosidase by the combination of red yeast rice xanthophyll and red yeast rice xanthophyll (150:300);

[0032] Figure 16 The inhibitory activity of the combination of red yeast rice xanthophyll and red yeast rice (150:400) on α-glucosidase;

[0033] Figure 17 Fa-CI curve of α-glucosidase by the combination of red yeast rice xanthophyll and red yeast rice xanthophyll (150:400);

[0034] Figure 18 The inhibitory activity of the combination of red yeast rice xanthophyll and red yeast rice (200:300) on α-glucosidase;

[0035] Figure 19 Fa-CI curve of α-glucosidase by the combination of red yeast rice xanthophyll and red yeast rice xanthophyll (200:300); Detailed Implementation

[0036] Unless otherwise stated, the terminology used in this invention generally has the meanings commonly understood by those skilled in the art.

[0037] Monascin is a type of red yeast rice pigment, a polyketide compound with the molecular formula: C2 21 H 26O5; Molecular weight: 358.43; CAS Registry Number: 21516-68-7; Structural formula:

[0038]

[0039] Ankaflavin is a type of pigment found in red yeast rice. It is a polyketide compound with the molecular formula C2. 24 H 32 O5; Molecular weight: 386.48; CAS Registry Number: 50980-32-0; Structural formula:

[0040]

[0041] α-Glucosidase (Saccharomyces cerevisiae, EC 3.2.1.20, Shanghai Yuanye Biotechnology Co., Ltd.);

[0042] 4-Nitrophenyl-α-D-glucopyranoside (pNPG, Tianjin Xins Biochemical Technology Co., Ltd.);

[0043] Acarbose (Shanghai Yuanye Biotechnology Co., Ltd.);

[0044] Red yeast rice extract and red yeast rice flavonoids (Chengdu Gechun Biopharmaceutical Co., Ltd.);

[0045] Anhydrous disodium hydrogen phosphate, anhydrous sodium dihydrogen phosphate (Shanghai Yi'en Chemical Technology Co., Ltd.), anhydrous sodium carbonate, dimethyl sulfoxide (Tianjin Bohua Chemical Reagent Co., Ltd.), hydrochloric acid (Sinopharm Chemical Reagent Co., Ltd.);

[0046] Infinite M200 PRO microplate reader (Tecan, Switzerland).

[0047] The in vitro inhibition experiment of α-glucosidase by acarbose, monaxanthin, and monaxanthin is as follows:

[0048] Phosphate buffer (PBS, 0.1M, pH 6.8): Accurately weigh 1.20g NaH2PO4 and dissolve it in 100mL of distilled water, and weigh 1.42g Na2HPO4 and dissolve it in 100mL of distilled water. Take appropriate amounts of the two solutions and mix them well to obtain 0.1M pH 6.8 phosphate buffer, and store it at 4℃.

[0049] α-glucosidase stock solution: Accurately weigh 3.00 mg of α-glucosidase (33 U / mg), dissolve it in the above PBS solution to prepare an enzyme stock solution of 0.30 mg / mL, dilute the stock solution to 60 μg / mL and store at -20℃.

[0050] 4-Nitrophenyl-α-D-glucopyranoside (pNPG) solution: Accurately weigh 15 mg of powdered pNPG, dissolve it in 10 mL of the above PBS solution, and mix thoroughly to obtain 5.0 × 10⁻⁶ ppm. -3 Prepare a mol / L pNPG stock solution for immediate use and store protected from light.

[0051] Acarbose solution: Weigh a certain amount of acarbose and dissolve it in the above buffer solution. Mix it thoroughly to obtain a 0.1 mol / L acarbose stock solution. Dilute with phosphate buffer before use.

[0052] Na2CO3 solution: Accurately weigh 2.12g of Na2CO3 powder and dissolve it in 100mL of ultrapure water to obtain a 0.2mol / L Na2CO3 solution.

[0053] Red yeast rice flavonoid solution: Accurately weigh 7.73 mg (M) of red yeast rice flavonoid. W =386.49 g / mol), dissolved in 10 mL of DMSO solution, yielding a concentration of 2.0 × 10⁻⁶ g / mol. -3 The stock solution is prepared at mol / L and stored away from light.

[0054] Monascus purpureus solution: Accurately weigh 7.17 mg (M) of monascus purpureus. W =358.6 g / mol), dissolved in 10 mL of DMSO solution, yielding a concentration of 2.0 × 10⁻⁶. -3 The stock solution is prepared at mol / L and stored away from light.

[0055] Specifically

[0056] In the reaction system, different concentrations of acarbose and AK or MS combination solutions diluted with PBS (0.1M, pH 6.8) were added sequentially (20 μL), along with α-glucosidase solution (7.5 μg / mL, 50 μL). After mixing, the mixture was incubated at 37°C for 6 min. Then, substrate pNPG (5.0 mM, 50 μL) preheated at 37°C for 5 min was added to the reaction solution. After mixing, the mixture was incubated at a constant temperature (37°C) for 30 min. Finally, 100 μL of 0.2 M Na2CO3 solution was added to terminate the reaction, and the absorbance was measured at a wavelength of 405 nm.

[0057] Calculation formula: Inhibition rate = [1 - (OD sample - OD blank) / (OD negative control - OD blank)] × 100%

[0058] The CI value calculated using the software CompuSyn is used to evaluate the synergistic effect between drugs.

[0059] The Combination Index (CI) is used to describe the strength of drug synergy: CI < 1, CI = 1, and CI > 1 represent synergistic, additive, and antagonistic effects between drugs, respectively. Synergistic effects indicate that combined use enhances the efficacy of each individual drug; the smaller the CI value, the stronger the synergistic effect. Additive effects indicate that the result of combined use is simply a linear summation of the efficacy of each individual drug. Antagonistic effects indicate that combined use may actually reduce the efficacy of each drug individually.

[0060] The present invention will be further described below with reference to specific embodiments and data. The following embodiments are merely illustrative of the invention and are not intended to limit the scope of the invention in any way.

[0061] Example 1

[0062] The composition of acarbose and monaxanthin contains a molar ratio of acarbose to monaxanthin of 400:300; specifically, the concentrations of acarbose and monaxanthin in the composition are 400 μM and 300 μM, respectively.

[0063] Example 2

[0064] The composition of acarbose and monaxanthin contains a molar ratio of acarbose to monaxanthin of 400:400; specifically, the concentrations of acarbose and monaxanthin in the composition are 400 μM and 400 μM, respectively.

[0065] Example 3

[0066] The composition of acarbose and monaxanthin contains a molar ratio of acarbose to monaxanthin of 600:300; specifically, the concentrations of acarbose and monaxanthin in the composition are 600 μM and 300 μM, respectively.

[0067] Example 4

[0068] The composition of acarbose and monaxanthin contains a molar ratio of acarbose to monaxanthin of 400:150; specifically, the concentrations of acarbose and monaxanthin in the composition are 400 μM and 150 μM, respectively.

[0069] Example 5

[0070] The composition of acarbose and monaxanthin contains a molar ratio of acarbose to monaxanthin of 400:200; specifically, the concentrations of acarbose and monaxanthin in the composition are 400 μM and 200 μM, respectively.

[0071] Example 6

[0072] The composition of acarbose and monaxanthin contains a molar ratio of acarbose to monaxanthin of 400:150; specifically, the concentrations of acarbose and monaxanthin in the composition are 600 μM and 150 μM, respectively.

[0073] Example 7

[0074] The composition of monaxanthin and monaxanthin contains a molar ratio of 150:300; specifically, the concentrations of monaxanthin and monaxanthin in the composition are 150 μM and 300 μM, respectively.

[0075] Example 8

[0076] The composition of monaxanthin and monaxanthin contains a molar ratio of 150:400 for monaxanthin and monaxanthin, respectively; specifically, the concentrations of monaxanthin and monaxanthin in the composition are 150 μM and 400 μM, respectively.

[0077] Example 9

[0078] The composition of monaxanthin and monaxanthin contains a molar concentration ratio of 200:300; specifically, the concentrations of monaxanthin and monaxanthin in the composition are 200 μM and 300 μM, respectively.

[0079] The present invention will be further described below with reference to specific embodiments and data:

[0080] The data are derived from the results of three independent experiments and are expressed as mean ± standard deviation.

[0081] This invention first provides the concentration range and IC50 values ​​for the inhibitory effects of monaxitin, monaxitoflavone, and acarbose on α-glucosidase. 50 Values ​​such as Figure 1 As shown: the IC50 of the red monazine, red monazine xanthophyll, and acarbose. 50 The values ​​were 317.58±1.51μM, 124.58±2.45μM and 386.75±2.55μM, respectively. The inhibitory ability of the three inhibitors on the enzyme was in the order of monaxioca xanthophyll > monaxioca xanthophyll > acarbose.

[0082] The inhibitory activity of acarbose and monaxitone (400:300) on α-glucosidase and the Fa-CI curves in Example 1 are shown below. Figure 2 and Figure 3 As shown:

[0083] The inhibitory activities of acarbose and monaxitol in a molar ratio of 400:300 on α-glucosidase at different concentration gradients are as follows: Figure 2As shown, the concentration gradients of acarbose and monaxanthin are (μM): 400+300, 200+150, 100+75, 50+37.5; wherein, the concentration gradient of acarbose is (μM): 400, 200, 100, 50; and the concentration gradient of monaxanthin is (μM): 300, 150, 75, 37.5. The acarbose and monaxanthin (400:300) composition at different concentrations improves the inhibitory activity against α-glucosidase.

[0084] Figure 3 The results showed that the combination drug coefficient of acarbose and monaxillin (400:300) was less than 1, indicating a synergistic effect. The CI values ​​at doses of 87.50, 175.00, 350.00, and 700.00 μM were 0.62, 0.60, 0.57, and 0.54, respectively, demonstrating a strong synergistic effect.

[0085] The inhibitory activity of acarbose and monaxitone (400:400) on α-glucosidase and the Fa-CI curves in Example 2 are shown below. Figure 4 and Figure 5 As shown:

[0086] The inhibitory activities of acarbose and monaxitol in a molar ratio of 400:400 on α-glucosidase at different concentration gradients are as follows: Figure 4 As shown, the concentration gradients of acarbose and monaxanthin are (μM): 400+400, 200+200, 100+100, 50+50; wherein, the concentration gradient of acarbose is (μM): 400, 200, 100, 50; and the concentration gradient of monaxanthin is (μM): 400, 200, 100, 50. The acarbose and monaxanthin (400:400) composition at different concentrations improves the inhibitory activity against α-glucosidase.

[0087] from Figure 5 The results showed that the combination drug coefficient of acarbose and monaxillin (400:400) was less than 1, indicating a synergistic effect. The CI values ​​at doses of 100.00, 200.00, 400.00, and 800.00 μM were 0.94, 0.83, 0.82, and 0.85, respectively, showing a slight synergistic effect.

[0088] The inhibitory activity of acarbose and monaxitone (600:300) on α-glucosidase and the Fa-CI curve in Example 3 are shown below. Figure 6 and Figure 7 As shown:

[0089] from Figure 7The results showed that the combination drug coefficient of acarbose and monaxillin (600:300) was greater than 1, indicating an antagonistic effect. The CI values ​​at doses of 112.50, 225.00, 450.00, and 900.00 μM were 1.85, 1.66, 1.56, and 1.55, respectively, showing a strong antagonistic effect.

[0090] The inhibitory activity of acarbose and monaxanthin (400:150) on α-glucosidase and the Fa-CI curves in Example 4 are shown below. Figure 8 and Figure 9 As shown:

[0091] The inhibitory activities of acarbose and monaxanthin in a molar ratio of 400:150 on α-glucosidase at different concentration gradients are as follows: Figure 8 As shown, the concentration gradients of acarbose and monaxanthin are (μM): 400+150, 200+75, 100+37.5, 50+18.75; wherein, the concentration gradient of acarbose is (μM): 400, 200, 100, 50; and the concentration gradient of monaxanthin is (μM): 150, 75, 37.5, 18.75. The acarbose and monaxanthin (400:150) composition at different concentrations improves the inhibitory activity against α-glucosidase.

[0092] from Figure 9 The results showed that the combination drug coefficient of acarbose and red yeast rice (400:150) was less than 1, indicating a synergistic effect. The CI values ​​at doses of 68.75, 137.50, 275.00, and 550.00 μM were 0.53, 0.56, 0.54, and 0.52, respectively, demonstrating a strong synergistic effect.

[0093] Example 5 shows the inhibitory activity of acarbose and monaxanthin (400:200) against α-glucosidase and the Fa-CI curves as follows: Figure 10 and Figure 11 As shown:

[0094] The inhibitory activities of acarbose and monaxanthin in a molar ratio of 400:200 on α-glucosidase at different concentration gradients are as follows: Figure 10 As shown, the concentration gradients of acarbose and monaxanthin are (μM): 400+200, 200+100, 100+50, 50+25; wherein, the concentration gradient of acarbose is (μM): 400, 200, 100, 50; and the concentration gradient of monaxanthin is (μM): 200, 100, 50, 25. The acarbose and monaxanthin (400:200) composition at different concentrations improves the inhibitory activity against α-glucosidase.

[0095] from Figure 11The results showed that the combination drug coefficient of acarbose and red yeast rice (400:200) was less than 1, indicating a synergistic effect. The CI values ​​at doses of 75.00, 150.00, 300.00 and 600.00 μM were 0.79, 0.83, 0.79 and 0.71, respectively, indicating a moderate synergistic effect.

[0096] The inhibitory activity of acarbose and monaxanthin (600:150) on α-glucosidase and the Fa-CI curves in Example 6 are shown below. Figure 12 and Figure 13 As shown:

[0097] from Figure 13 The results showed that the combination drug coefficient of acarbose and red yeast rice (600:150) was greater than 1, indicating an antagonistic effect. Among them, the CI values ​​at doses of 93.75, 187.50, 375.00 and 750.00 μM were 1.59, 1.37, 1.43 and 1.34, respectively, showing a moderate antagonistic effect.

[0098] Example 7 shows the inhibitory activity of α-glucosidase and the Fa-CI curve of monaxitin and monaxitin (150:300). Figure 14 and Figure 15 As shown:

[0099] The inhibitory activities of α-glucosidase on Monascus xanthophyll and Monascus fuciformis at different concentration gradients with a molar ratio of 150:300 are as follows: Figure 14 As shown, the concentration gradients of the red yeast rice flavonoid and red yeast rice syrup (μM) are: 150+300, 75+150, 37.5+75, 18.75+37.5; wherein, the concentration gradient of red yeast rice flavonoid (μM) is: 150, 75, 37.5, 18.75; and the concentration gradient of red yeast rice syrup (μM) is: 300, 150, 75, 37.5. The red yeast rice flavonoid and red yeast rice syrup (150:300) composition at different concentrations improved the inhibitory activity against α-glucosidase.

[0100] from Figure 15 The results showed that the combined drug coefficient of monaxanthin and monaxanthin (150:300) was less than 1, indicating a synergistic effect. The CI values ​​at doses of 56.25, 112.50, 225.00, and 450.00 μM were 0.51, 0.57, 0.64, and 0.67, respectively, demonstrating a strong synergistic effect.

[0101] Example 8 shows the inhibitory activity of α-glucosidase by monaxanthin and monaxanthin (150:400) and the Fa-CI curve. Figure 16 and Figure 17 As shown:

[0102] The inhibitory activities of α-glucosidase on monaxitin and monaxitin at different concentration gradients with a molar ratio of 150:400 are as follows: Figure 16 As shown, the concentration gradients of the red yeast rice flavonoid and red yeast rice syrup were (μM): 150+400, 75+200, 37.5+100, 18.75+50; wherein, the concentration gradient of red yeast rice flavonoid was (μM): 150, 75, 37.5, 18.75; and the concentration gradient of red yeast rice syrup was (μM): 400, 200, 100, 50. The red yeast rice flavonoid and red yeast rice syrup (150:400) composition at different concentrations improved the inhibitory activity against α-glucosidase.

[0103] from Figure 17 The results showed that the combined drug coefficients of monaxanthin and monaxanthin (150:400) were between 0.9 and 1.1. Among them, the CI values ​​at doses of 68.75, 137.50, 275.00 and 550.00 μM were 1.06, 1.05, 1.07 and 1.09, respectively, showing an additive effect.

[0104] Example 9 shows the inhibitory activity of α-glucosidase and the Fa-CI curve of monaxitin and monaxitin (200:300). Figure 18 and Figure 19 As shown:

[0105] The inhibitory activities of α-glucosidase on monaxitin and monaxitin at different concentration gradients with a molar ratio of 200:300 are as follows: Figure 18 As shown, the concentration gradients of the red yeast rice flavonoid and red yeast rice syrup are (μM): 200+300, 100+150, 50+75, 25+37.5; wherein, the concentration gradient of red yeast rice flavonoid is (μM): 200, 100, 50, 25; and the concentration gradient of red yeast rice syrup is (μM): 300, 150, 75, 37.5. The red yeast rice flavonoid and red yeast rice syrup (200:300) composition at different concentrations improved the inhibitory activity against α-glucosidase.

[0106] from Figure 19 The results showed that the combined drug coefficient of monaxanthin and monaxanthin (200:300) was less than 1, indicating a synergistic effect. The CI values ​​at doses of 62.50, 125.00, 250.00, and 500.00 μM were 0.69, 0.77, 0.75, and 0.81, respectively, indicating a moderate synergistic effect.

[0107] The above are some typical embodiments of the present invention and are not intended to limit the present invention in any way. Those skilled in the art can obviously combine and modify the methods and applications described in this invention based on the technology and content of this invention to achieve the technology of this invention. In particular, any simple substitutions, modifications, and combinations made to the above embodiments based on this invention without departing from the essence of the technical solution of this invention still fall within the protection scope of this invention.

Claims

1. A pharmaceutical composition having a blood glucose-lowering effect, characterized by comprising, It contains acarbose and monaxanthin in a molar ratio of 400:300 or 400:400; or it contains acarbose and monaxanthin in a molar ratio of 400:150 or 400:200.

Images